Giant cell arteritis (GCA) is the most frequent primary systemic vasculitis in adults, involving medium-to-large-sized ...

Delays in starting tocilizumab therapy for giant cell arteritis are caused partly by delays in insurance approval, and costs ...

SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck.

Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday that its FDA-approved anti-inflammatory agent Cosentyx failed to reach the main goal in a Phase 3 trial for adults with giant cell arteritis ((GCA) ...

The Food and Drug Administration (FDA) has approved Rinvoq ® (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with giant cell arteritis (GCA).. The approval was based ...

Giant cell arteritis (GCA) is a medical emergency. The concept of symptom-to-thrombolysis time in myocardial infarction and stroke is well established.

Sustained remission. The new trial included 100 sites across 24 countries. Patients with giant cell arteritis treated daily with prednisone were randomized to one of three different groups: the ...

ZURICH (Reuters) -Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the arteries ...

WASHINGTON — Upadacitinib 15 mg is superior to placebo for achieving sustained remission in giant cell arteritis across patient subgroups based on age, sex and glucocorticoid experience ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis. AbbVie on Tuesday said the European Commission's nod ...

Patients with giant cell arteritis treated daily with prednisone were randomized to one of three different groups: the control group that received placebo medications; a group that received 7.5 ...